Cognition gets its Series A

Biotech start-up Cognition Therapeutics has rounded up $1.2 million for its Series A. Cognition hopes to develop a new therapy for Alzheimer's disease. New York-based Ogden CAP LLC led the round with M5Invest Partners, Innovation Works and Pittsburgh Life Sciences Greenhouse adding to the round with individual investors. Report

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.